Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab ... time a medicine has shown a clinical benefit in basal cell carcinoma patients who have progressed or are ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

REGN is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...

Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and data on linvoseltamab for relapsed or refractory multiple myeloma. Other research ...

in the treatment of basal cell carcinoma (BCC), with positive data outcomes. The study included patients who had relapsed after standard therapies and had no other treatment options. Among them, three ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...